ClinicalTrials.gg

Program

IBI3042

A development code. Also written as “Investigational Drug: IBI3042”.

Its studies are mostly in Obesity, led by Innovent Biologics.

Furthest: phase 1, since Aug 20, 20262 company-led studies, 2 open or runningNext primary completion: Feb 3, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics22 open or runningphase 1since Aug 20, 2026Aug 20, 2026Feb 3, 2027phase 1 · NCT07842393

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2026First study: phase 1 study in OverweightFirst studyNCT07793019 · 104 planned · China
  2. Sep 16, 2026Phase 1 study in Healthy Volunteers (HV)NCT07842393 · 32 planned · United States

Ahead

  1. Feb 3, 2027Primary completion: phase 1 study in Healthy Volunteers (HV)NCT07842393
  2. Sep 6, 2027Primary completion: phase 1 study in OverweightNCT07793019

TargetBeta

GLP1R →read by rule
“The goal of this study is to learn about the safety and tolerability of IBI3042, an investigational oral drug that activates the glucagon-like peptide-1 (GLP-1) receptor.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07842393Healthy Volunteers (HV) · United States1Not yet recruitingFeb 3, 202732
NCT07793019Overweight · China1RecruitingSep 6, 2027104

How it is read

Names in the registry

  • “Investigational Drug: IBI3042”, 1 entry
  • “IBI3042”, 1 entry

Codes read as this program: IBI3042.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
IBI3042 (Innovent Biologics): development program | ClinicalTrials.gg